Diana De Santis1, Falana Sheriff1, Deborah Bester2, Rabia Shahab3, Carolyn Hutzal4. 1. Michael G. DeGroote School of Medicine, McMaster University, Waterloo Regional Campus, Kitchener, Ontario. 2. Respiratory Therapy, Grand River Hospital, Kitchener, Ontario. 3. Data Integration and Reporting Specialist Department, Grand River Hospital, Kitchener, Ontario. 4. Department of Pediatrics, Grand River Hospital, Kitchener, Ontario.
Abstract
BACKGROUND: High-flow nasal cannula (HFNC) is a form of noninvasive respiratory support used for paediatric acute respiratory illnesses. Past HFNC research has focused on its use in bronchiolitis and in intensive care units, but little is reported on its use in the community hospital setting. We aimed to investigate the paediatric population using HFNC, any adverse events, and risk factors for deterioration. METHODS: A retrospective chart review was performed on patients admitted to a community paediatric ward. Inclusion criteria were patients between 1 day and 17 years of age, admitted between September 2013 and April 2016, and treated with HFNC for at least 4 hours. RESULTS: A total of 85 children met inclusion criteria. The average age of patients in our study was 3.41 years with 39% of patients >2 years of age. 46% of patients had an admitting diagnosis of bronchiolitis, 33% pneumonia, and 16% with asthma. Transfer rate to tertiary care centre paediatric intensive care unit was 18%. Patients transferred required greater FIO2 (odds ratio [OR] 1.04, P=0.018, confidence interval [CI] 1.007 to 1.082), and were 3.2 times more likely to be positive for respiratory syncytial virus (RSV) (P=0.081, CI 0.868-11.739). There were no adverse events attributed to HFNC in the population. CONCLUSION: HFNC is being utilized in the community hospital setting for children of varied age and types of respiratory illnesses. Children requiring higher FIO2 are at risk of respiratory deterioration which may identify them earlier for transfer to tertiary care. Further research into the safety and efficacy of HFNC for different paediatric illnesses in the community is needed.
BACKGROUND: High-flow nasal cannula (HFNC) is a form of noninvasive respiratory support used for paediatric acute respiratory illnesses. Past HFNC research has focused on its use in bronchiolitis and in intensive care units, but little is reported on its use in the community hospital setting. We aimed to investigate the paediatric population using HFNC, any adverse events, and risk factors for deterioration. METHODS: A retrospective chart review was performed on patients admitted to a community paediatric ward. Inclusion criteria were patients between 1 day and 17 years of age, admitted between September 2013 and April 2016, and treated with HFNC for at least 4 hours. RESULTS: A total of 85 children met inclusion criteria. The average age of patients in our study was 3.41 years with 39% of patients >2 years of age. 46% of patients had an admitting diagnosis of bronchiolitis, 33% pneumonia, and 16% with asthma. Transfer rate to tertiary care centre paediatric intensive care unit was 18%. Patients transferred required greater FIO2 (odds ratio [OR] 1.04, P=0.018, confidence interval [CI] 1.007 to 1.082), and were 3.2 times more likely to be positive for respiratory syncytial virus (RSV) (P=0.081, CI 0.868-11.739). There were no adverse events attributed to HFNC in the population. CONCLUSION: HFNC is being utilized in the community hospital setting for children of varied age and types of respiratory illnesses. Children requiring higher FIO2 are at risk of respiratory deterioration which may identify them earlier for transfer to tertiary care. Further research into the safety and efficacy of HFNC for different paediatric illnesses in the community is needed.
Authors: Gregorio P Milani; Anna M Plebani; Elisa Arturi; Danila Brusa; Susanna Esposito; Laura Dell'Era; Emanuela A Laicini; Dario Consonni; Carlo Agostoni; Emilio F Fossali Journal: Acta Paediatr Date: 2016-05-16 Impact factor: 2.299
Authors: Donna Franklin; Franz E Babl; Luregn J Schlapbach; Ed Oakley; Simon Craig; Jocelyn Neutze; Jeremy Furyk; John F Fraser; Mark Jones; Jennifer A Whitty; Stuart R Dalziel; Andreas Schibler Journal: N Engl J Med Date: 2018-03-22 Impact factor: 91.245
Authors: Elizabeth Kepreotes; Bruce Whitehead; John Attia; Christopher Oldmeadow; Adam Collison; Andrew Searles; Bernadette Goddard; Jodi Hilton; Mark Lee; Joerg Mattes Journal: Lancet Date: 2017-02-02 Impact factor: 79.321